These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 15230945)
1. Safety and supply of haemophilia products: worldwide perspectives. Farrugia A Haemophilia; 2004 Jul; 10(4):327-33. PubMed ID: 15230945 [TBL] [Abstract][Full Text] [Related]
2. Product delivery in the developing world: options, opportunities and threats. Farrugia A Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376 [TBL] [Abstract][Full Text] [Related]
3. Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product? Farrugia A Haemophilia; 2004 Oct; 10 Suppl 4():83-7. PubMed ID: 15479377 [TBL] [Abstract][Full Text] [Related]
4. Emerging and receding risks of therapeutic regimens for haemophilia. Farrugia A; Manno CS; Evatt BL Haemophilia; 2004 Oct; 10 Suppl 4():47-54. PubMed ID: 15479372 [TBL] [Abstract][Full Text] [Related]
5. Evolving perspectives in product safety for haemophilia. Farrugia A Haemophilia; 2002 May; 8(3):236-43. PubMed ID: 12010417 [TBL] [Abstract][Full Text] [Related]
6. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. Batlle J; Villar A; Liras A; Alonso C; Altisent C; Brito D; Moreno M; Lucía F; Sedano C; Prieto M; Calvente N; Aznar JA; Jiménez V; Soriano V; Martorell JR; Iruín G; Bergua JM; Aguilar C Blood Coagul Fibrinolysis; 2008 Jul; 19(5):333-40. PubMed ID: 18600079 [TBL] [Abstract][Full Text] [Related]
7. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. Josephson CD; Abshire TC Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540 [TBL] [Abstract][Full Text] [Related]
8. Globalisation and blood safety. Farrugia A Blood Rev; 2009 May; 23(3):123-8. PubMed ID: 19081166 [TBL] [Abstract][Full Text] [Related]
15. Changing pattern of care of boys with haemophilia in western European centres. Chambost H; Ljung R; Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909 [TBL] [Abstract][Full Text] [Related]
16. World Federation of Haemophilia programs in developing countries. Giangrande PL; Black C Semin Thromb Hemost; 2005 Nov; 31(5):555-60. PubMed ID: 16276464 [TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
18. Products for clotting factor replacement in developing countries. Kasper CK Semin Thromb Hemost; 2005 Nov; 31(5):507-12. PubMed ID: 16276458 [TBL] [Abstract][Full Text] [Related]
19. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors]. Habart D Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398 [TBL] [Abstract][Full Text] [Related]
20. International movement of plasma and plasma contracting. Farrugia A Dev Biol (Basel); 2005; 120():85-96. PubMed ID: 16050160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]